FDA Clearance Tracker · P030054-S440
Promote/+/RF/Q, Promote Accel, Promote Quadra, Unify, Unify Assura, Unify Quadra, Quadra Assura, Epic+/HF/HF+/II HF/II+
Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 21, 2026
Approved
Time to decision
203 days
Received Dec 30, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P030054-S440
- Device name
- Promote/+/RF/Q, Promote Accel, Promote Quadra, Unify, Unify Assura, Unify Quadra, Quadra Assura, Epic+/HF/HF+/II HF/II+
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Sylmar, CA
- Received
- Dec 30, 2025
- Decided
- Jul 21, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P030054
Device type
- Device type
- Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D) (NIK)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
approval for Merlin 2 Patient Care System (PCS) programmer support for the AVEIR Leadless Pacemakers.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.